6 research outputs found
Delineation of the clinical phenotype associated with non-mosaic type-2 NF1 deletions: two case reports
Introduction
Large deletions of the NF1 gene and its flanking regions are frequently associated with a severe clinical manifestation. Different types of gross NF1 deletion have been identified that are distinguishable both by their size and the number of genes included within the deleted regions. Type-1 NF1 deletions encompass 1.4 Mb and include 14 genes, whereas the much less common type-2 NF1 deletions span 1.2 Mb and contain 13 genes. Genotype-phenotype correlations in patients with large NF1 deletions are likely to be influenced by the nature and number of the genes deleted in addition to the NF1 gene. Whereas the clinical phenotype associated with type-1 NF1 deletions has been well documented, the detailed clinical characterization of patients with non-mosaic type-2 NF1 deletions has not so far been reported.
Case presentation
In the present report we characterized two Caucasian European patients with non-mosaic (germline) type-2 NF1 deletions. Our first patient was a 13-year-old girl with dysmorphic facial features, mild developmental delay, large hands and feet, hyperflexibility of the joints, macrocephaly and T2 hyperintensities in the brain. A whole-body magnetic resonance imaging scan indicated two internal plexiform neurofibromas. Our second patient was an 18-year-old man who exhibited dysmorphic facial features, developmental delay, learning disability, large hands and feet, hyperflexibility of the joints, macrocephaly and a very high subcutaneous and internal tumor load as measured volumetrically on whole-body magnetic resonance imaging scans. At the age of 18 years, he developed a malignant peripheral nerve sheath tumor and died from secondary complications. Both our patients exhibited cardiovascular malformations.
Conclusions
Our two patients with non-mosaic type-2 NF1 deletions exhibited clinical features that have been reported in individuals with germline type-1 NF1 deletions. Therefore, a severe disease manifestation is not confined to only patients with type-1 NF1 deletions but may also occur in individuals with type-2 NF1 deletions. Our findings support the concept of an NF1 microdeletion syndrome with severe clinical manifestation that is caused by type-1 as well as type-2 NF1 deletions
Extended runs of homozygosity at 17q11.2: an association with type-2NF1 deletions?
Large deletions in the NF1 gene region at
17q11.2 are caused by nonallelic homologous recombination
(NAHR). The recurrent type-2 NF1 deletions
span 1.2 Mb, with breakpoints in the SUZ12 gene and
SUZ12P. Type-2 NF1 deletions occur preferentially
during mitosis and are associated with somatic mosaicism.
A panel of 16 type-2 NF1 deletions was used as a
model system in which to investigate whether extended
homozygosity across 17q11.2 might be associated with
somatic deletion. Using SNP arrays, a 3.2Mb interval
encompassing the NF1 deletion region was found to
harbor runs of homozygosity (ROHs) in different human
populations. However, ROHs Z500 kb directly flanking
the NF1 deletion region on both sides were not found to
occur disproportionately in NF1 patients harboring type-
2 deletions compared to controls. Although low allelic
diversity in 17q11.2 is unlikely to be a key factor in
promoting NAHR-mediated somatic type-2 deletions, a
specific ROH of 588 kb (roh1), located some 525 kb
proximal to the deletion interval, was found to occur
more frequently (P50.012) in the type-2 deletion
patients compared with controls. We postulate that
roh1 may act remotely, via an as yet unknown mechanism,
to increase the frequency of somatic recombination
between the distally duplicated SUZ12 sequences
Tissue-specific differences in the proportion of mosaic large NF1 deletions are suggestive of a selective growth advantage of hematopoietic del(+/-) stem cells
Type-2 NF1 deletions spanning 1.2 Mb are frequently of postzygotic origin and hence tend to be associated with mosaicism for normal cells and those harboring the deletion (del(+/−) cells). Eleven patients with mosaic type-2 deletions were investigated by FISH and high proportions (94–99%) of del(+/−) cells were detected both in whole blood and in isolated CD3+, CD14+, CD15+, and CD19+ leukocytes. Significantly lower proportions of del(+/−) cells (24-82%) were however noted in urine-derived epithelial cells. A patient harboring an atypical large NF1 deletion with nonrecurrent breakpoints was also found to have a much higher proportion of del(+/−) cells in blood (96%) than in urine (51%). The tissue-specific differences in the proportions of del(+/−) cells as well as the X chromosome inactivation (XCI) patterns observed in these mosaic patients suggest that the majority of the deletions had occurred before or during the preimplantation blastocyst stage before the onset of XCI. We postulate that hematopoietic del(+/−) stem cells present at an early developmental stage are characterized by a selective growth advantage over normal cells lacking the deletion, leading to a high proportion of del(+/−) cells in peripheral blood from the affected patients
Delineation of the clinical phenotype associated with non-mosaic type-2 NF1 deletions: two case reports
Characterization of the nonallelic homologous recombination hotspot PRS3 associated with type-3 NF1 deletions
Nonallelic homologous recombination (NAHR) is the major mechanism underlying recurrent genomic rearrangements, including the large deletions at 17q11.2 that cause neurofibromatosis type 1 (NF1). Here we identify a novel NAHR hotspot, responsible for type-3 NF1 deletions which span 1.0-Mb. Breakpoint clustering within this 1-kb hotspot, termed PRS3, was noted in 10 of 11 known type-3 NF1 deletions. PRS3 is located within the LRRC37B pseudogene of the NF1-REPb and NF1-REPc low-copy repeats. In contrast to other previously characterized NAHR hotspots, PRS3 has not developed on a pre-existing allelic homologous recombination hotspot. Furthermore, the variation pattern of PRS3 and its flanking regions are unusual since only NF1-REPc (and not NF1-REPb) is characterized by a high SNP frequency, suggestive of uni-directional sequence transfer via nonallelic homologous gene conversion (NAHGC). By contrast, the previously described intense NAHR hotspots within the CMT1A-REPs, and the PRS1 and PRS2 hotspots underlying type-1 NF1 deletions, experience frequent bi-directional sequence transfer. PRS3 within NF1-REPc was also found to be involved in NAHGC with the LRRC37B gene, the progenitor locus of the LRRC37B-P duplicons, as indicated by the presence of shared SNPs between these loci. PRS3 therefore represents a weak (and probably evolutionarily rather young) NAHR hotspot with unique properties. ©2011 Wiley Periodicals, Inc.status: publishe